NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised $110 million by offering 6.5 million shares at $17, the high end of the range of $15 to $17. NexImmune originally filed to sell 4.7 million shares, before increasing the offering to 5.9 million shares on Thursday, and further upsizing the deal at pricing. Existing shareholders had intended to purchase $20 million worth of shares in the offering.
NexImmune plans to list on the Nasdaq under the symbol NEXI. Barclays, Cantor Fitzgerald, Raymond James and Allen & Company acted as lead managers on the deal.
